Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H32O13S |
Molecular Weight | 656.654 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12COC(=O)[C@]1([H])[C@H](C3=CC(OC)=C(O)C(OC)=C3)C4=C(C=C5OCOC5=C4)[C@H]2O[C@]6([H])O[C@]7([H])CO[C@H](O[C@@]7([H])[C@H](O)[C@H]6O)C8=CC=CS8
InChI
InChIKey=NRUKOCRGYNPUPR-QBPJDGROSA-N
InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
Molecular Formula | C32H32O13S |
Molecular Weight | 656.654 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094255 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VUMON Approved UseTeniposide Injection, in combination with other approved anticancer agents, is indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia. Launch Date7.1107202E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7083.9 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/4017164 |
30 mg/m² single, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
TENIPOSIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1937.3 μg × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/4017164 |
30 mg/m² single, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
TENIPOSIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/4017164 |
30 mg/m² single, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
TENIPOSIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
TENIPOSIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Other AEs: Infection, Neutropenia... Other AEs: Infection (grade 5, 1 patient) Sources: Neutropenia (grade 4, 15 patients) Neutropenia (grade 3, 8 patients) Neutropenia (grade 1-2, 6 patients) Anemia (grade 3, 4 patients) Anemia (grade 1-2, 20 patients) Thrombocytopenia (grade 3, 3 patients) Thrombocytopenia (grade 1-2, 8 patients) Infection (grade 3, 4 patients) Infection (grade 1-2, 1 patient) Fever (grade 1-2, 2 patients) Nausea (grade 3, 1 patient) Nausea (grade 1-2, 19 patients) Vomiting (grade 3, 1 patient) Vomiting (grade 1-2, 8 patients) Hyponatremia (grade 4, 1 patient) |
165 mg/m2 2 times / week multiple, intravenous Recommended Dose: 165 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 165 mg/m2, 2 times / week Co-administed with:: cytarabine(300 mg/m2, twice weekly for 8 to 9 doses) Sources: |
unhealthy, children Health Status: unhealthy Condition: acute lymphoblastic leukemia Age Group: children Sources: |
Other AEs: Myelosuppression, Anaphylactic reaction... Other AEs: Myelosuppression (severe) Sources: Anaphylactic reaction |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Infection | grade 1-2, 1 patient | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Nausea | grade 1-2, 19 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Fever | grade 1-2, 2 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Anemia | grade 1-2, 20 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Neutropenia | grade 1-2, 6 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Thrombocytopenia | grade 1-2, 8 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Vomiting | grade 1-2, 8 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Nausea | grade 3, 1 patient | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Vomiting | grade 3, 1 patient | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Thrombocytopenia | grade 3, 3 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Anemia | grade 3, 4 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Infection | grade 3, 4 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Neutropenia | grade 3, 8 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Hyponatremia | grade 4, 1 patient | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Neutropenia | grade 4, 15 patients | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Infection | grade 5, 1 patient | 60 mg/m2 5 times / 3 weeks multiple, intravenous Dose: 60 mg/m2, 5 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 5 times / 3 weeks Sources: |
unhealthy, 64 years (range: 46–83 years) n = 41 Health Status: unhealthy Condition: small cell lung carcinoma Age Group: 64 years (range: 46–83 years) Sex: M+F Population Size: 41 Sources: |
Anaphylactic reaction | 165 mg/m2 2 times / week multiple, intravenous Recommended Dose: 165 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 165 mg/m2, 2 times / week Co-administed with:: cytarabine(300 mg/m2, twice weekly for 8 to 9 doses) Sources: |
unhealthy, children Health Status: unhealthy Condition: acute lymphoblastic leukemia Age Group: children Sources: |
|
Myelosuppression | severe | 165 mg/m2 2 times / week multiple, intravenous Recommended Dose: 165 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 165 mg/m2, 2 times / week Co-administed with:: cytarabine(300 mg/m2, twice weekly for 8 to 9 doses) Sources: |
unhealthy, children Health Status: unhealthy Condition: acute lymphoblastic leukemia Age Group: children Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 64 uM] | likely (co-administration study) Comment: see http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Teniposide_monograph_1July2014.pdf#page=4 for list of interactions Sources: https://pubmed.ncbi.nlm.nih.gov/11770832/ |
|||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | likely (co-administration study) Comment: see http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Teniposide_monograph_1July2014.pdf#page=4 for list of interactions Sources: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Teniposide_monograph_1July2014.pdf#page=4 Page: 4.0 |
|||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Lung cancer: therapeutic options for stage IV and recurrent NSCLC. | 2001 |
|
Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide. | 2001 Dec |
|
Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). | 2001 Dec 7 |
|
Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma. | 2001 Feb |
|
Anticancer drugs induce increased mitochondrial cytochrome c expression that precedes cell death. | 2001 Feb 1 |
|
Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release. | 2001 Feb 23 |
|
Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma. | 2001 Jan |
|
Evaluation of teniposide (VM-26)-induced toxicity on mouse spermatogenesis by flow cytometry. | 2001 Jun 21 |
|
Leukemias related to treatment with DNA topoisomerase II inhibitors. | 2001 May |
|
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. | 2001 May |
|
Atp-bound topoisomerase ii as a target for antitumor drugs. | 2001 May 11 |
|
26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. | 2001 Nov 2 |
|
Diva/Boo is a negative regulator of cell death in human glioma cells. | 2001 Sep 7 |
|
Active, but not inactive, human centromeres display topoisomerase II activity in vivo. | 2002 |
|
Assessment of drug activity and proliferation ex vivo for prediction of outcome in aggressive non-Hodgkin's lymphomas. | 2002 |
|
Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. | 2002 Aug |
|
No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study. | 2002 Feb |
|
Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin. | 2002 Feb 1 |
|
DNA topoisomerase II is essential for preimplantation mouse development. | 2002 Mar |
|
Effect of the DNA topoisomerase II inhibitor VP-16 on illegitimate recombination in yeast chromosomes. | 2002 May 29 |
|
[Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens]. | 2002 Nov |
|
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. | 2003 |
|
Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. | 2003 Apr 15 |
|
[Evaluation of efficacy of treatment for 30 children with neuroblastoma]. | 2003 Dec |
|
Dental abnormalities in children after chemotherapy treatment for acute lymphoid leukemia. | 2003 Jan |
|
Interactions between antiepileptic and chemotherapeutic drugs. | 2003 Jul |
|
Enhanced production of podophyllotoxin by Podophyllum hexandrum using in situ cell retention bioreactor. | 2003 May-Jun |
|
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | 2003 Nov 17 |
|
Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase -2. | 2003 Sep-Dec |
|
Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. | 2004 |
|
Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs. | 2004 Apr 15 |
|
[Significance of C-reaction protein for differential diagnosis of fever after chemotherapy on children with acute lymphoblastic leukemia]. | 2004 Jul |
|
[Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma]. | 2004 May |
|
Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. | 2004 Sep |
|
Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. | 2004 Sep 15 |
Sample Use Guides
Teniposide Injection must be diluted with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP, to give final teniposide concentrations of 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, or 1.0 mg/mL. It is recommended that the teniposide solution be administered over at least a 30- to 60-minute period.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:16:05 UTC 2023
by
admin
on
Sat Dec 16 16:16:05 UTC 2023
|
Record UNII |
957E6438QA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000000176
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
||
|
FDA ORPHAN DRUG |
883
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
||
|
WHO-ATC |
L01CB02
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
||
|
WHO-VATC |
QL01CB02
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
||
|
LIVERTOX |
NBK548102
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
||
|
NDF-RT |
N0000175609
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
||
|
NCI_THESAURUS |
C1331
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m10558
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | Merck Index | ||
|
10362
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | RxNorm | ||
|
122819
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
100000082949
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
75988
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
CHEMBL452231
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
452548
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
1643736
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
C857
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
DTXSID8023638
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
6546
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
2590
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
6843
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
957E6438QA
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
D013713
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
249-831-2
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
DB00444
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
SUB10895MIG
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
TENIPOSIDE
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
3836
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY | |||
|
29767-20-2
Created by
admin on Sat Dec 16 16:16:06 UTC 2023 , Edited by admin on Sat Dec 16 16:16:06 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |